無料プレビュー

Corvus Pharmaceuticals, Inc. (CRVS) · NASDAQ Global Market

プロフィール

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule and monoclonal antibody product candidates targeting immune cell function and the tumor microenvironment. Its lead candidate, soquelitinib, an ITK inhibitor in Phase 3 trials for relapsed peripheral T cell lymphoma and Phase 2 trials for atopic dermatitis, is designed to modulate T cell differentiation and reduce inflammatory cytokine production. The company also develops ciforadenant, an A2A receptor antagonist, and mupadolimab, an anti-CD73 antibody, both for solid tumors. Corvus relies on contract

主要指標

株価: $10.21 (-1.92%)
時価総額: 9億ドル
PER（今期予想）: -13.7
PBR: 4.2
配当利回り: —
52週レンジ: $6.39 – $26.95
業種: Healthcare / Biotechnology
上場: NASDAQ Global Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-03 · 更新: 2026-10-09